Company intelligence / Profile preview
Trueline Therapeutics
Cambridge, Massachusetts, United Statestruelinetx.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Trueline Therapeutics has completed IND-enabling studies for its lead MCL1 inhibitor TTX‑810, a macrocyclic small molecule designed for rapid clearance and high potency in treating solid and hematologic tumors. The company is preparing to initiate clinical development. Additional pipeline assets include a bispecific T-cell engager targeting CD3 x CD33 in Phase 1 for myelodysplastic syndromes and other preclinical/discontinued programs.
- Therapeutic areas
- OncologyHematology
- Modalities
- Small moleculeBispecific T-cell engager (BiTE)Macrocyclic compound
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
03
Partnerships
Broad Institute of Harvard/MIT
Beyond the preview
Go deeper on Trueline Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Trueline Therapeutics.